

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-13. (Canceled)

Claim 14. (Previously Presented): The method as claimed in Claim 17, wherein the anti-P-LAP antibody is an anti-human P-LAP antibody.

Claim 15. (Previously Presented): The method as claimed in Claim 17, wherein the anti-P-LAP antibody is an anti-human P-LAP polyclonal antibody.

Claim 16. (Canceled)

Claim 17. (Currently Amended): A method for prognostic evaluation of a P-LAP positive ovarian carcinoma in a patient, comprising:

(a) contacting P-LAP positive ovarian carcinoma tissues obtained from said patient with an anti-P-LAP antibody,

(b) measuring the intensity of the specific antigen-antibody binding between P-LAP present in the ovarian carcinoma tissues and anti-P-LAP antibody, and

(c) ~~correlating the intensity of the specific antigen-antibody binding with a ten-year disease-free survival rate (DFS) of said patient~~ determining that a ten-year disease-free survival

rate (DFS) of said patient decreases as the intensity of the specific antigen-antibody binding increases.